Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.VGX Pharmaceuticals has announced that the FDA has approved its investigational new drug application for its DNA vaccine for cervical cancer therapy, VGX-3100.
Subscribe to our email newsletter
The company expects to initiate the Phase I clinical study for VGX-3100 in patients in a multi-center study in the third quarter of 2008.
VGX-3100 is said to be the first of the company’s several proprietary SynCon DNA vaccine candidates delivered by its Cellectra electroporation device planned to enter Phase I clinical testing.
Joseph Kim, president and CEO of VGX, said: “We are pleased with the FDA’s acceptance of our VGX-3100 investigational new drug (IND) application for treating cervical cancer. This accomplishment further demonstrates the potential and efficiency of our DNA-based product development platform.”